In 2022, we conducted a survey of our English- and French-language patient communities to gather patient-reported experience measures (PREMs) related to the experiences of adults with cutaneous melanoma in Canada. The survey focussed on side effects, the current care landscape, and the holistic experience of cutaneous melanoma. One segment of the survey focussed on the experience of those who received Pembrolizumab (Keytruda™) for stage II melanoma. We invite you to read the report here or by clicking on the image below. If you have any questions, please email

As always, we are grateful to our community of patients who offer their time and stories to us. You are the reason we fight for equitable and timely access to melanoma, ocular melanoma, and non-melanoma skin cancer care for all Canadians.